|
A healthy hedge.(Fariba Ghodsian of Castle Creek LifeScience Partners)
Publication: Buyside Publication Date: 01-MAR-03 Author: Leerskov, Meghan
|
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2003 Adams Business Media
Fariba Ghodsian
Castle Creek LifeScience Partners
Biotechnology's constant pace of innovation makes it an enthralling sector for investment opportunities. Pushing the boundaries of discovery provides the possibility for unprecedented gains and losses. When navigating this "final frontier," it helps to have a proven guide like Fariba Ghodsian.
Ghodsian, who currently heads up research for Castle Creek LifeScience Partners' $85 million biotech hedge fund, has had her fingers on the pulse of the industry for more than a decade. Ghodsian was a director of healthcare research at...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from Buyside |
Taurum Capital Partners are offering a new real estate fund, the Pacif...
March 01, 2003
|
Waddell & Reed Financial acquired the business of Mackenzie Investment...
March 01, 2003
|
Credit Suisse Asset Management.( Richard White named portfolio manager...
March 01, 2003
|
Franklin Templeton Investments Corp.(Buyside on the buy side: who's mo...
March 01, 2003
|
Oppenheimer Funds (OFI), and Tremont Advisers announced the launch of ...
March 01, 2003
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
